COVID-19 Pandemic: Disease Management and Current Therapeutics
Abstract
The highly contagious disease COVID-19, caused by SARS-CoV-2, has emerged as a global pandemic. The high rate of contact transmission of this virus is the major cause of concern nowadays. Owing to the absence of any effective drugs/vaccines against COVID-19, many countries adopted ‘lockdown’ to minimize transmission of virus. The other means that was applied during lockdown, to mitigate the growth of infection is the ‘test, trace, track and isolate’. However, different countries responded differently to these control measures with different outcome in the growth of infection. For now, several countries have started ‘unlock’, to handle the severe economic stress, created in response to lockdown. Again, lifting lockdown is another global threat, having the chance of second wave of infection. In such situation, the major challenge is to prevent the spread of infection, amid resumption of work. The present review is aimed to outline the prospect and future direction of disease management and current therapeutics against COVID-19.
How to cite this article:
Chanda I, Pan A, Pranavathiyani G. COVID-19 Pandemic: Disease Management and Current Therapeutics. J Commun Dis 2020; 52(4): 29-34.
DOI: https://doi.org/10.24321/0019.5138.202037
References
Lu R, Zhao X, Li J et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications
for virus origins and receptor binding. Lancet 2020; 395: 565-574.
McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses 2014;
: 2991-3018.
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and
the miracle. J Med Virol 2020; 92: 401-402.
Liu Y, Gayle AA, Wilder-Smith A et al. The reproductive number of COVID-19 is higher compared to SARS
coronavirus. J Travel Med 2020; 27(2): taaa021.
Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations.
Available from: https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-viruscausing-
COVID-19-implications-for-ipc-precautionrecommendations.Accessed on: 4 Jun 2020.
van Doremalen N, Bushmaker T, Morris DH et al. Aerosol and surface stability of SARS-CoV-2 as compared with
SARS-CoV-1. N Engl J Med 2020; 382: 1564-7.
Hoffmann M, Kleine-Weber H, Schroeder S et al. SARSCoV-2 cell entry depends on ACE2 and TMPRSS2 and
is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271-80.e8.
Sungnak W, Huang N, Bécavin C et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells
together with innate immune genes. Nat Med 2020; 26: 681-687.
Coronavirus. Available from: https://www.who.int/health-topics/coronavirus. Accessed on: 4 June 2020.
Rose DU, Piersigilli F, Ronchetti MP et al. Novel Coronavirus disease (COVID-19) in new-borns and
infants: what we know so far. Italian Journal of Paediatrics 2020; 46: 56.
Statement - Older people are at highest risk from COVID-19, but all must act to prevent community
spread. 2020 Available from: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-
COVID-19/statements/statement-older-people-areat-highest-risk-from-COVID-19,-but-all-must-act-toprevent-
community-spread. Published on: Apr 2, 2020. Accessed on: 4 June 2020.
Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute Respiratory Syndrome
Coronavirus 2 While Presymptomatic or Asymptomatic. Emerging Infectious Diseases 2020. Available from:
https://wwwnc.cdc.gov/eid/article/26/7/20-1595_article. Accessed on: 4 June 2020.
Khanna R, Cicinelli M, Gilbert S et al. COVID-19 pandemic: Lessons learned and future directions. Indian Journal of Ophthalmology 2020; 68(5): 703-710.
Coronavirus Update (Live): 7,477,428 Cases and 419,373 Deaths from COVID-19 Virus Pandemic - Worldometer.Available from: https://www.worldometers.info/coronavirus/. Accessible on: Jun 15, 2020.
WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 May 2020. Available from:
COVID-19---11-may-2020. Accessible on: 4 June, 2020.
Li B-Z, Cao N-W, Zhou H-Y et al. Strong policies control the spread of COVID-19 in China. J Med Virol 2020.
Pan A, Liu L, Wang C et al. Association of public health interventions with the epidemiology of the COVID-19
Outbreak in Wuhan, China. JAMA 2020; 323(19): 1-9.
PTI. WHO lauds India’s “tough and timely†actions against corona virus. The Hindu, 2020.
Ghosal S, Bhattacharyya R, Majumder M. Impact of complete lockdown on total infection and death rates:
A hierarchical cluster analysis. Diabetes MetabSyndr 2020; 14: 707-711.
Peng Z, Song W, Ding Z et al. Linking key intervention timings to rapid declining effective reproduction number to quantify lessons against COVID-19. Front Med., 2020.
Sweden to ramp up coronavirus testing. Available from:https://medicalxpress.com/news/2020-05-swedenramp-coronavirus.html. Accessible on: 4 June, 2020.
Patel R, Babady E, Theel ES et al. Report from the American Society for Microbiology COVID-19
International Summit, 23 March 2020: value of diagnostic testing for SARS-CoV-2/COVID-19. MBio
; 11(2): e00722-20.
Giordano G, Blanchini F, Bruno R et al. Modelling the COVID-19 epidemic and implementation of populationwide interventions in Italy. Nat Med 2020; 26: 855-860.
Chatterjee K, Chatterjee K, Kumar A et al. Healthcare impact of COVID-19 epidemic in India: A stochastic
mathematical model. Armed Forces Med J India 2020; 76(2): 147-155.
Kim S. FDA gives emergency authorization for new antigen test to help detect coronavirus quicker and
cheaper. 2020.
Normile D. Coronavirus cases have dropped sharply in South Korea. What’s the secret to its success? Science,
BBC News. Infection rate rises in Germany as lockdown eases. BBC News, 2020.
Reality Check team. Coronavirus: China’s plan to test everyone in Wuhan. BBC News, 2020.
Meyer R. There’s One Big Reason the U.S. Economy Can’t Reopen. The Atlantic, 2020.
Chaturvedi A. 50-day lockdown, relaxation for 30 days: British scientists suggest new model to beat COVID-19.
Hindustan Times, 2020.
AP. Brazil becoming coronavirus hot spot as testing falters. The Hindu, 2020.
Al Jazeera News. Peru extends nationwide lockdown until end of June, 2020.
BBC News. India records highest spike in COVID-19 cases. BBC News, 2020.
HT Correspondent. One-third of migrant workers could be infected with COVID-19: Centre tells SC. Hindustan
Times, 2020.
ABC News. Wuhan records first new COVID cases since lockdown was lifted. ABC News, 2020.
Stedman M, Davies M, Lunt M et al. A phased approach to unlocking during the COVID-19 pandemic-Lessons
from trend analysis. Int J Clin Pract 2020; 00: e13528.
Stedman M, Lunt M, Davies M et al. COVID-19: Modelling Local Transmission and Morbidity
effects to provide an estimate of overall Relative Healthcare Resource Impact by General Practice
Granularity. Available from: https://www.medrxiv.org/content/10.1101/2020.03.20.20039024v1. Accessible
on: 4 June, 2020.
Chang R, Wang H, Zhang S et al. Phase- and epidemic region-adjusted estimation of the number of coronavirus disease 2019 cases in China. Front Med 2020; 14: 199-209.
Roques L, Klein EK, Papaïx J et al. Impact of lockdown on the epidemic dynamics of COVID-19 in France. Frontiers in Medicine, 2020.
Sardar T, Nadim SS, Chattopadhyay J. Assessment of 21 days lockdown effect in some states and overall India: A predictive mathematical study on COVID-19 outbreak. Chaos Solitons Fractals 2020; 139: 110078.
Xu C, Dong Y, Yu X et al. Estimation of reproduction numbers of COVID-19 in typical countries and epidemic
trends under different prevention and control scenarios. Front Med 2020, 1-10.
WHO. Landscape analysis of therapeutics as 21st March 2020. Available from: https://www.who.int/blueprint/
priority-diseases/key-action/Table_of_therapeutics_Appendix_17022020.pdf.
Desk W. Russia to use antiviral drug Favipiravir against COVID-19. 2020. Available from: https://www.theweek.in/news/world/2020/04/07/russia-to-use-antiviraldrug-favipiravir-against-COVID-19.html.
Gilead Announces Approval of Veklury® (Remdisivir) in Japan for patients with severe COVID-19. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/5/gilead-announces-approval-ofveklury-remdesivir-in-japan-for-patients-with-severe-COVID19.
Found effective drug combination to cure COVID-19 patients: Bangladeshi doctors. 2020. Available
from: https://www.hindustantimes.com/indianews/found-effective-drug-combination-to-cure-
COVID-19-patients-bangladeshi-doctors/story-K8z0YQD43b2KbptPQAwLdO.html.
Blood thinners may improve survival among hospitalized COVID-19 patients: Research could change standard of care protocols to prevent clotting associated with coronavirus. 2020. Available from: https://www.
sciencedaily.com/releases/2020/05/200507194907.html.
Peter K. Blood thinners as a treatment for COVID-19? What the science says and what it means for you.
Available from: https://medicalxpress.com/news/2020-05-blood-thinners-treatment-COVID-science.html.
Rintatolimod and IFN Alpha-2b for the treatment of mild or moderate COVID-19 infection in cancer patients.
Available: from: https://clinicaltrials.gov/ct2/show/ NCT04379518.
Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19. Med Hypotheses 2020;
: 109802.
WHO. Draft landscape of COVID-19 candidate vaccines. Available: from: https://www.who.int/who-documentsdetail/draft-landscape-of-covid-19-candidate-vaccines.
Copyright (c) 2020 Journal of Communicable Diseases (E-ISSN: 2581-351X & P-ISSN: 0019-5138)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
